Investor Presentation First Nine Months of 2023
136
Investor presentation
First nine months of 2023
North America Operations at a glance.
NAO
Diabetes trend in population
Diabetes market by value and
Novo Nordisk market share
Novo Nordisk reported sales
Million
DKK
MS
billion
First nine months of
2023
Sales
(MDKK)
Growth²
70
10%
Injectable GLP-13
48,719
43%
60
11%
900
80%
RybelsusⓇ
7,537
46%
50
Total GLP-1
56,256
43%
60%
4320
40
600
Total insulin4
7,763
-24%
GLP-1
Other Diabetes care5
459
-22%
30
63
57
40%
51
46.6%1
Diabetes care
64,478
29%
20
10
300
1.5%1
Insulin
Obesity care
24,384
244%
20%
Diabetes & Obesity
OAD
88,862
55%
17.7%1
care
0
2021
0
0%
2030
2045
Aug
2018
Aug
2023
Rare disease?
Total
5,146
-13%
94,008
49%
Population with diabetes
Diabetes growth rate
GLP-1 MS
-Insulin MS
-OAD MS
International Diabetes Federation: Diabetes Atlas 1th Edition
2000 and Diabetes Atlas 10th Edition 2021
1 CAGR calculated for 5-year period
Competitor insulin value market shares, as of Aug 2023: Novo Nordisk 42%,
Others 58%; Competitor GLP-1 value market shares, as of Aug 2023: Novo
Nordisk 53%, Others 47%. OAD: Oral anti-diabetic; MS: Market Share; Source:
IQVIA MAT, Aug 2023 value figures; Market values are based on the list prices
2 At constant exchange rates; 3 Comprises Victoza®, Ozempic®;
4 Comprises Tresiba®, XultophyⓇ, Levemir®, NovoMix®, Fiasp® and NovoRapidⓇ;
5Comprises Novo NormⓇ and needles; 6 Comprises SaxendaⓇ and WegovyⓇ
7Comprises primarily NovoSeven®, Novo Eight® Esperoct®, NovoThirteenⓇ,
Refixia, Norditropin®, Vagifem® and ActivelleⓇView entire presentation